Top member reports
Consensus community valuation
$0.250
Average Intrinsic Value
363%
Undervalued by
Active Member Straws
#ASX Announcements
Added a week ago

Ann: Imugene Receives Second PD1-VAXX Ethics Trial Approval

 

IMUGENE RECEIVES SECOND ETHICS APPROVAL TO START PHASE I CLINICAL TRIAL OF NEW CANCER IMMUNOTHERAPY PD1-VAXX IN AUSTRALIA _______________________________________________________________________________________ • Macquarie University hospital receives human research ethics approval for Phase I human trial of anti-cancer immunotherapy PD1-Vaxx • Patient screening scheduled to commence in August • Ethics approval represents 2nd independent review of PD1-Vaxx pre- clinical safety and efficacy data SYDNEY, Australia, 17 July 2020:

 

View Attachment

Read More
#Bull Case
Added 6 months ago

And in case you missed it from a few weeks ago

Imugene will trial PD1-Vaxx in patients with non-small cell lung cancer

Will 2020 be the start of immunotherapy dishing out a fatal blow to many forms of cancer? I hope so!

Read More
#Bull Case
Last edited 6 months ago

Imugene has checkvacc preclinical data published in the journal of american college of surgeons

Positive results for pancreatic cancer but pushing ahead with testing in patients with Triple-Negative Breast Cancer (TNBC) which had equally positive pre-clinical data.

Read More